Ranbaxy Laboratories

Sun Pharma closes merger deal with Ranbaxy

Thursday, March 26, 2015

Sun Pharmaceutical Industries has begun the integration of Ranbaxy‘s business following the successful closure of its merger. The integration, planned by Sun Pharma since the announced merger in April 2014, will focus on supporting strong growth. According to Sun Pharma, the merger has fortified its position as the world’s fifth largest specialty generic pharmaceutical company and the top ranking Indian pharma company.

[Read More]

Gilead collaborates with Indian partners to reduce costs, improve availability of antiretroviral therapy

Thursday, August 2, 2012

Pharmaceutical companies Gilead Sciences, Mylan Laboratories, Ranbaxy Laboratories and Strides Arcolab have entered into agreements to collaborate on promoting access to high-quality, low-cost generic versions of Gilead’s HIV medicine emtricitabine (FTC) in developing countries, including single tablet regimens containing emtricitabine and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines.

[Read More]

Furiex’s phase II PPD-10558 trial does not meet primary efficacy endpoint

Friday, December 9, 2011

Furiex Pharmaceuticals has reported top-line results from the phase II trial of the investigational drug PPD-10558 in patients with statin-associated myalgia, or SAM. PPD-10558 did not meet its primary efficacy endpoint in this randomized, double-blind, proof-of-concept study. The study enrolled patients with high cholesterol and a prior history of SAM, and evaluated recurrence rates for SAM over a twelve-week treatment period across the following three different treatment regimens: placebo; PPD-10558; and atorvastatin (Lipitor). Patients did not report any significant differences in muscle symptoms, nor did they drop out due to SAM in significantly different percentages, among the three regimens. As expected, however, PPD-10558, a novel statin, did significantly lower LDL-cholesterol compared with placebo, and the compound also had a favorable safety profile.

[Read More]